Logos Global Management LP cut its holdings in shares of Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX – Free Report) by 24.8% during the 2nd quarter, Holdings Channel.com reports. The firm owned 4,700,000 shares of the company’s stock after selling 1,550,000 shares during the quarter. Logos Global Management LP’s holdings in Lineage Cell Therapeutics were worth $4,687,000 as of its most recent SEC filing.
Several other hedge funds and other institutional investors also recently bought and sold shares of LCTX. Price T Rowe Associates Inc. MD lifted its holdings in shares of Lineage Cell Therapeutics by 77.5% during the first quarter. Price T Rowe Associates Inc. MD now owns 161,314 shares of the company’s stock valued at $239,000 after purchasing an additional 70,418 shares during the last quarter. Comerica Bank boosted its stake in shares of Lineage Cell Therapeutics by 84,745.8% during the 1st quarter. Comerica Bank now owns 250,295 shares of the company’s stock worth $370,000 after acquiring an additional 250,000 shares in the last quarter. Fifth Third Wealth Advisors LLC bought a new stake in shares of Lineage Cell Therapeutics during the 1st quarter worth about $30,000. DCF Advisers LLC boosted its stake in Lineage Cell Therapeutics by 14.5% during the 4th quarter. DCF Advisers LLC now owns 94,751 shares of the company’s stock valued at $103,000 after purchasing an additional 12,000 shares during the period. Finally, XTX Topco Ltd bought a new stake in Lineage Cell Therapeutics during the 2nd quarter valued at approximately $61,000. 62.47% of the stock is currently owned by hedge funds and other institutional investors.
Analysts Set New Price Targets
Separately, Craig Hallum assumed coverage on Lineage Cell Therapeutics in a report on Tuesday, August 20th. They set a “buy” rating and a $4.00 price objective on the stock.
Lineage Cell Therapeutics Price Performance
LCTX stock opened at $0.94 on Tuesday. Lineage Cell Therapeutics, Inc. has a fifty-two week low of $0.77 and a fifty-two week high of $1.61. The stock has a market cap of $178.04 million, a PE ratio of -6.73 and a beta of 1.26.
Lineage Cell Therapeutics (NYSEAMERICAN:LCTX – Get Free Report) last released its quarterly earnings data on Thursday, August 8th. The company reported ($0.03) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.04) by $0.01. The firm had revenue of $1.41 million for the quarter, compared to analyst estimates of $1.28 million. Lineage Cell Therapeutics had a negative return on equity of 36.30% and a negative net margin of 391.00%. As a group, equities research analysts anticipate that Lineage Cell Therapeutics, Inc. will post -0.12 EPS for the current fiscal year.
About Lineage Cell Therapeutics
Lineage Cell Therapeutics, Inc, a clinical-stage biotechnology company, develops novel cell therapies for unmet medical needs in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the dry age-related macular degeneration; OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries; and VAC, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer.
Featured Stories
- Five stocks we like better than Lineage Cell Therapeutics
- 3 Stocks to Protect Your Portfolio from the Coronavirus Contagion
- 4 Reasons GlobalFoundries Could Be a Big Winner After Recent Lows
- Industrial Products Stocks Investing
- The Average 401k Balance by Age Explained
- What Does a Gap Up Mean in Stocks? How to Play the Gap
- 3 Uranium Stocks To Gain as Microsoft Goes Nuclear to Power AI
Want to see what other hedge funds are holding LCTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX – Free Report).
Receive News & Ratings for Lineage Cell Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lineage Cell Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.